Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05994534Phase 1Recruiting

PK and PD Study of NPI-001 and Cysteamine Bitartrate

Role: lead

NCT05026632Phase 1Active Not Recruiting

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Role: lead

NCT04355689Phase 1Active Not Recruiting

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

Role: lead

NCT07290530Phase 3Not Yet Recruiting

24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Role: lead

All 4 trials loaded